Lekozotan

Lekozotan
(IUPAC) ime
	4-Cijano-N-[(2R)-2-[4-(2,3-dihidro-1,4-benzodioksin-5-il)-1-piperazinil]propil]-N-2-piridinilbenzamid hidrohlorid
Klinički podaci
Identifikatori
CAS broj	434283-16-6
ATC kod	nije dodeljen
PubChem	11156648
UNII	48854OTZ5E
KEGG	D04683
Hemijski podaci
Formula	C28H30ClN5O3
Mol. masa	520,021 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C28H29N5O3.ClH/c1-21(31-13-15-32(16-14-31)24-5-4-6-25-27(24)36-18-17-35-25)20-33(26-7-2-3-12-30-26)28(34)23-10-8-22(19-29)9-11-23;/h2-12,21H,13-18,20H2,1H3;1H ; Key: GXYZREDEYDFJPT-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Lekozotan potencijalni lek za poboljšanje kognitivnih funkcija kod obolelih od Alchajmerove bolesti.^[4]^[5]

Metod dejstva uredi

Lekozotan je kompetitivni, selektivni antagonist 5-HT_1A receptor^[6] koji povišava kalijumom stimulisano otpuštanje acetilholina i glutamata.^[7]

Reference uredi

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ H. Spreitzer (2008-08-13). „Neue Wirkstoffe - Lecozotan” (German). Österreichische Apothekerzeitung (17/2007): 805.
↑ ClinicalTrials
↑ Schlechter, LE; Smith, DL; Rosenzweig-Lipson, S; Sukoff, SJ; Dawson, LA; Marquis, K; Jones, D; Piesla, M i dr.. (2005-06-10). „Lecotozan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and promotes procognitive effects”. Journal of Pharmacology and Experimental Therapeutics 314 (3): 1274. DOI:10.1124/jpet.105.086363. PMID 15951399. Arhivirano iz originala na datum 2007-09-07. Pristupljeno 2014-04-05.
↑ Childers, WE Jr, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE (2007). „Lecozotan Hydrochloride”. Drugs of the Future 32 (5): 399–407. DOI:10.1358/dof.2007.032.05.1092901.

Spoljašnje veze uredi

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[4] H. Spreitzer (2008-08-13). „Neue Wirkstoffe - Lecozotan” (German). Österreichische Apothekerzeitung (17/2007): 805.

[5] ClinicalTrials

[6] Schlechter, LE; Smith, DL; Rosenzweig-Lipson, S; Sukoff, SJ; Dawson, LA; Marquis, K; Jones, D; Piesla, M i dr.. (2005-06-10). „Lecotozan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and promotes procognitive effects”. Journal of Pharmacology and Experimental Therapeutics 314 (3): 1274. DOI:10.1124/jpet.105.086363. PMID 15951399. Arhivirano iz originala na datum 2007-09-07. Pristupljeno 2014-04-05.

[7] Childers, WE Jr, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE (2007). „Lecozotan Hydrochloride”. Drugs of the Future 32 (5): 399–407. DOI:10.1358/dof.2007.032.05.1092901.

[4]

[5]

[1]

[2]

[3]

[6]

[7]